Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups

被引:58
作者
Leung, GM [1 ]
Lim, WW
Ho, LM
Lam, TH
Ghani, AC
Donnelly, CA
Fraser, C
Riley, S
Ferguson, NM
Anderson, RM
Hedley, AJ
机构
[1] Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China
[2] Harvard Univ, Sch Publ Hlth, Takemi Program, Boston, MA 02115 USA
[3] Publ Hlth Lab Ctr, Govt Virus Unit, Kowloon, Hong Kong, Peoples R China
[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London, England
基金
英国惠康基金;
关键词
D O I
10.1017/S0950268805004826
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.
引用
收藏
页码:211 / 221
页数:11
相关论文
共 51 条
  • [1] [Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P986
  • [2] [Anonymous], 2013, WHOCDSCSRGAR2003
  • [3] New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia
    Arden, KE
    Nissen, MD
    Sloots, TP
    Mackay, IM
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2005, 75 (03) : 455 - 462
  • [4] Breiman RF, 2003, EMERG INFECT DIS, V9, P1037
  • [5] CHAN FKL, 2004, HOSP AUTH CONV 2004, P85
  • [6] Severe acute respiratory syndrome-associated coronavirus infection
    Chan, PKS
    Ip, M
    Ng, KC
    Chan, RCW
    Wu, A
    Lee, N
    Rainer, TH
    Joynt, GM
    Sung, JJY
    Tam, JS
    [J]. EMERGING INFECTIOUS DISEASES, 2003, 9 (11) : 1453 - 1454
  • [7] Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome
    Che, XY
    Qiu, LW
    Pan, YX
    Wen, K
    Hao, W
    Zhang, LY
    Wang, YD
    Liao, ZY
    Hua, X
    Cheng, VCC
    Yuen, KY
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (06) : 2629 - 2635
  • [8] Healthcare worker seroconversion in SARS outbreak
    Chow, PKH
    Ooi, EE
    Tan, HK
    Ong, KW
    Sil, BK
    Teo, M
    Ng, T
    Soo, KC
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (02) : 249 - 250
  • [9] HUMAN CORONAVIRUS OC43 INTERACTS WITH MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULES AT THE CELL-SURFACE TO ESTABLISH INFECTION
    COLLINS, AR
    [J]. IMMUNOLOGICAL INVESTIGATIONS, 1994, 23 (4-5) : 313 - 321
  • [10] METAANALYSIS IN CLINICAL-TRIALS
    DERSIMONIAN, R
    LAIRD, N
    [J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188